Part 3 – Case Discussion & Wrap-up
Brian A. Jonas, MD, PhD, FACP, presents the case of patient “A.B.” to fellow faculty members Daniel A. Pollyea, MD, MS and Gabriel N. Mannis, MD. The virtual roundtable panel discusses unique features of the case and offers insights into how the latest data from clinical trials may impact the future of treatment for patients with acute myeloid leukemia (AML).
Disclosures: Brian A. Jonas, MD, PhD, FACP Consulting Fees: AbbVie, Genentech, GlycoMimetics, Jazz, Takeda Contracted Research: 47, AbbVie, Amgen, AROG, Celgene, Daiichi-Sankyo, Forma, Genentech/Roche, GMI, Hanmi, Jazz, Pfizer, PCYC Travel Reimbursement: AbbVie Gabriel N. Mannis, MD Consulting Fees: AbbVie, Agios, BMS/Celgene, Genentech, Pfizer Contracted Research: Gilead/Forty Seven, Glycomimetics, Jazz Daniel A. Pollyea, MD, MS Consulting Fees: Celgene, Abbvie, Genentech, Novartis, Karyopharm, Syndax, BMS Other: Takeda, Syros, Kiadis, Foghorn, Aprea, Gilead, Amgen, Astellas References:
- DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971. PMID: 32786187.
- Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 Feb 13;135(7):463-471. doi: 10.1182/blood.2019002140. PMID: 31841594; PMCID: PMC7019193.
- Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19. PMID: 30024784; PMCID: PMC6127025.
- Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019 Feb;33(2):379-389. doi: 10.1038/s41375-018-0312-9. Epub 2018 Dec 16. PMID: 30555165; PMCID: PMC6365492.
- Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Erratum in: Lancet. 2018 Feb 8;: PMID: 22482940.
